Kestra Medical Technologies, Ltd. (KMTS)

Kestra Medical Technologies’ first fiscal quarter of 2027 featured a revenue beat alongside an EPS miss, with results reported September 14, 2026. Revenue rose 59.9% to about $31.0 million, topping the $29.0 million estimate (+7%), as the company continued scaling its Cardiac Recovery System offering in cardiac monitoring, therapeutic treatment, and connected patient management. Profitability remained negative, with gross profit of roughly $17.5 million translating to a gross margin of about 57%, while operating margin came in at around -122% alongside operating income of about -$37.7 million. On the bottom line, net income was negative about $44.1 million, down 70.7% year over year from roughly -$25.8 million, and EPS of -$0.75 trailed the -$0.62 estimate by -$0.13. Cash generation also stayed pressured, with negative operating cash flow of about $32.3 million, and the company paid roughly $172,000 in dividends. Consensus for the next period calls for EPS of -$0.60 on revenue of $31.8 million.